Gregory Gerstner, MD
Basic profileGregory Gerstner is an Oncology physician affiliated with Illinois CancerCare. OpenAlex indexes 27 publications with 664 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GenentechProgram year202524 paymentsResearch$60,778
- Bristol Myers SquibbProgram year20253 paymentsResearch$25,775
- Merck & Co.Program year20251 paymentResearch$337
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.1%PD-1 inhibitor14.2%Pembrolizumab86%Atezolizumab14%Part B, office-administered≥26 patientsMicrotubule Inhibitor11.5%Paclitaxel83%Docetaxel17%Part B, office-administered≥28 patients+ 18 more classes in this area
Blood & clotting
29.1%Iron, parenteral preparations16.2%Ferric carboxymaltose100%Part B, office-administered≥25 patientsErythropoiesis-stimulating Agent10.2%Darbepoetin alfa100%Part B, office-administered≥13 patients+ 4 more classes in this area
Metabolism & gastrointestinal
13.9%Substance P/Neurokinin-1 Receptor Antagonist6.4%Aprepitant100%Part B, office-administered≥33 patientsOther antiemetics4.5%Fosaprepitant100%Part B, office-administered≥24 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Assessing safety and feasibility of virtual reality intervention in patients with lung cancer: a pilot study
Supportive Care in Cancer
2025 - The risk of venous and arterial thrombosis in polycythemia vera patients with secondary malignancies.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Veeder, MD
Illinois CancerCare
Gary Macvicar, MD
Illinois CancerCare
Nguyet Le-Lindqwister, MD
Illinois CancerCare
Francois Geoffroy, MD
Illinois CancerCare
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”